AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company developing ABP-450 (prabotulinumtoxinA), a botulinum toxin complex, for debilitating medical conditions with an initial focus on the neuroscience market. Its development programs target chronic and episodic migraine, cervical dystonia, gastroparesis, and post-traumatic stress disorder. The active biologic ingredient is the same botulinum toxin complex marketed cosmetically by Evolus under the name Jeuveau and manufactured by Daewoong Pharmaceutical. Investors follow the stock primarily for ABP-450's potential as a proposed biosimilar to BOTOX (onabotulinumtoxinA) and for milestones along its regulatory pathway. I checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Over the last 30 days, AEON declined approximately 51%, falling from a closing price near $0.23 in mid-October to $0.1134 by November 17, 2026. The move was punctuated by sharp single-session declines, including a drop of roughly 19% on November 17 alone. From what I see, this kind of rapid move often signals broader sentiment shifts beyond any single headline.
The quarterly trend is similarly negative. From a closing level near $0.26 in mid-August, the stock has fallen roughly 56% to its current price. The share price trades near the low end of its 52-week range of $0.1062 to $1.45, reflecting persistent selling pressure despite periodic news-driven rallies. One thing that stands out here is how consistently the lows have been tested.
Several verified developments shaped the recent decline. On September 30, 2026, the company announced receipt of FDA Type 2b meeting minutes clarifying ABP-450's development path as a proposed biosimilar to BOTOX, including a planned comparative pharmacodynamic (CMAP) study. On November 9, AEON submitted an investigational new drug (IND) application for that study. I also reviewed the setup with Tickeron’s AI Trend Prediction Engine to gauge potential follow-through on the regulatory steps.
Analyst sentiment was supportive in places, with Lake Street raising its price target to $2 from $1 while maintaining a Buy rating. However, financing dynamics outweighed the clinical news. The company's third-quarter 2026 report, released November 16, showed a quarterly net income of approximately $2.47 million versus a net loss of $4.54 million a year earlier, but a nine-month net loss of about $10.48 million and roughly $6.2 million in warrant exercises underscored continued share dilution.
A key catalyst was the accelerated expiration of two-year milestone warrants on November 16, 2026, triggered by the Type 2b minutes. The resulting conversions increased the share count and contributed to heavy selling. Concurrently, a proxy statement proposed a reverse stock split of between 1-for-2 and 1-for-100 to address NYSE American listing compliance, signaling ongoing concerns about the share price level.
The quarterly decline reflects a broader narrative of capital needs and shareholder dilution rather than a single clinical setback. AEON has relied on multiple financings to fund development, and a prior 1-for-72 reverse split took effect in February 2025. The ongoing warrant overhang, low share price, and listing-compliance considerations have weighed on sentiment even as the company received constructive regulatory feedback and maintained analyst Buy ratings. The result has been a steady multi-month downtrend with intermittent volatility.
Investors will be watching the December 15, 2026 special stockholder meeting, where shareholders vote on reverse-split authority and related proposals, and whether a split is ultimately implemented to support NYSE American compliance. Other key factors include the planned initiation of the CMAP study in the first quarter of 2027, progress toward an integrated evidence package for a potential Biologics License Application under the biosimilar pathway, and the company's ability to secure additional funding. Analysts have maintained favorable ratings with an average 12-month price target of $1.82, but realized value will depend on execution, financing, and regulatory outcomes. I’m watching this closely as the vote approaches. This article does not constitute financial advice or a prediction of future performance.
I often turn to Tickeron’s AI Trading Bots when evaluating names facing volatility and dilution pressures like this one. The platform gives access to hundreds of bots covering thousands of tickers, letting users compare strategies across different timeframes and risk levels. It has become a regular part of how I test ideas before committing capital.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
The Aroon Indicator for AEON entered a downward trend on November 13, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 177 similar instances where the Aroon Indicator formed such a pattern. In 156 of the 177 cases the stock moved lower. This puts the odds of a downward move at 88%.
The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AEON as a result. In 56 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 63%.
The Moving Average Convergence Divergence Histogram (MACD) for AEON turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 27 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 63%.
AEON moved below its 50-day moving average on November 03, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for AEON crossed bearishly below the 50-day moving average on October 19, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 53%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AEON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +14.99% 3-day Advance, the price is estimated to grow further. Considering data from situations where AEON advanced for three days, in 161 of 200 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
AEON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 55 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.571) is normal, around the industry mean (3.592). P/E Ratio (-0.039) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (442.120).
The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. AEON’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AEON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology